Health Care • Biotechnology: Pharmaceutical Preparations
$1.95 ▲ +0.06
(+3.18%)
MKT CAP: $7.8M • VOL: 772.3K
52W L $1 52W H $5
TCRT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.0K | $10.0K | $5.0K |
| YoY Revenue Growth % | -50.0% | +100.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$4.2M | -$4.8M | -$34.3M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$4.2M | -$4.7M | -$4.7M |
| EBITDA (Normalized) | -$4.1M | -$4.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$2.9M | -$5.0M | -$30.1M |
| Capital Expenditures (CapEx) | $98.0K | $0 | — |
| Free Cash Flow (FCF) | -$3.0M | -$5.0M | -$30.1M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $1.4M | $1.1M | — |
| Total Debt (Short + Long Term) | — | $0 | — |
| Total Stockholders' Equity | $2.2M | $2.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TCRT.